MedTrace Logo

400mcg Sublingual Misoprostol as First Line Treatment

NCT01939457 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 641

Last updated 2013-09-11

No results posted yet for this study

Summary

Women presenting with incomplete abortion and eligible for treatment with misoprostol were offered 400mcg sublingual misoprostol for treatment. Based on existing literature, the study hypothesises that women can successfully be treated with misoprostol alone as first line treatment.

Conditions

  • Incomplete Abortion

Interventions

DRUG

Misoprostol

Sponsors & Collaborators

  • Gynuity Health Projects

    lead OTHER

Principal Investigators

  • Beverly Winikoff, MD MPH · Gynuity Health Projects

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • Senegal

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01939457 on ClinicalTrials.gov